Bayer tweaks anti-counterfeiting tactics

A Bayer team from various corporate disciplines assigns anti-counterfeiting features to products based on evaluated risk level. Risk criteria include patient health ramifications, product properties, supply chain considerations and economic drivers, all considered in light of a potential counterfeiting scenario. 

The team then selects security features to incorporate with layout, design and packaging, an anonymous spokesperson tells Securing Pharma. The packaging for one critical medicine has seven security features that nearly assure complete protection against counterfeiting, according to the spokesperson. Most of these features can be seen with the naked eye, according to Bayer, although some require ultraviolet light and decoder templates.

But the effort doesn't stop there. Tie-ins with serialization and traceability efforts come next, followed by use of analytics for physical, chemical and packaging material.

- see the story

Suggested Articles

While no shortages of drug supplies have been reported, governments are trying to get a handle on what they can do if they materialize.

Branded drug sales in China could suffer in the short term as marketing activities for new meds are limited to reduce the risk of contagion.

Korean CDMO Samsung Biologics is expanding and China API maker WuXi STA opened a 30,000-square-foot oligonucleotide manufacturing facility.